Samuel C. Mok, Ph.D.

Peer-Reviewed Articles

1. Khlebus EY, Vuttaradhi VK, Ferri-Borgogno S, Brodsky AL, Lawson BC, Mok SC, Hillman RT. Multiplexed imaging mass cytometry reveals tumor-immune microenvironment-dependent hormone receptor expression in adult type ovarian granulosa cell tumors. Cancer Res Commun 5(10):1894-1909, 2025. e-Pub 2025. PMID: 41042551.
2. Chowdhury, S, Ferri-Borgogno, S, Yang, P, Wang, W, Peng, J, Mok, S, Wang, P. Learning directed acyclic graphs for ligands and receptors based on spatially resolved transcriptomic data of ovarian cancer. Briefings in bioinformatics 26(2), 2025. e-Pub 2025. PMID: 40062614.
3. Ng CW, Wong KK, Lawson BC, Ferri-Borgogno S, Mok SC. Spatial transcriptome reveals histology-correlated immune signature learnt by deep learning attention mechanism on H&E-stained images for ovarian cancer prognosis. J Transl Med 23(1):113, 2025. e-Pub 2025. PMID: 39856778.
4. Ferri-Borgogno, S, Burks, JK, Seeley, EH, McKee, TD, Stolley, D, Basi, A, Gomez, JA, Gamal, BT, Ayyadhury, S, Lawson, BC, Yates, MS, Birrer, MJ, Lu, KH, Mok, S. Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics Analyses. Cancers 16(5), 2024. e-Pub 2024. PMID: 38473208.
5. Han, C, Leonardo, TR, Romana-Souza, B, Shi, J, Keiser, S, Yuan, H, Altakriti, M, Ranzer, MJ, Ferri-Borgogno, S, Mok, S, Koh, TJ, Hong, SJ, Chen, L, DiPietro, LA. Microfibril-associated protein 5 and the regulation of skin scar formation. Scientific reports 13(1), 2023. e-Pub 2023. PMID: 37253753.
6. Chowdhury S, Kennedy JJ, Ivey RG, Murillo OD, Hosseini N, Song X, Petralia F, Calinawan A, Savage SR, Berry AB, Reva B, Ozbek U, Krek A, Ma W, da Veiga Leprevost F, Ji J, Yoo S, Lin C, Voytovich UJ, Huang Y, Lee SH, Bergan L, Lorentzen TD, Mesri M, Rodriguez H, Hoofnagle AN, Herbert ZT, Nesvizhskii AI, Zhang B, Whiteaker JR, Fenyo D, McKerrow W, Wang J, Schurer SC, Stathias V, Chen XS, Barcellos-Hoff MH, Starr TK, Winterhoff BJ, Nelson AC, Mok SC, Kaufmann SH, Drescher C, Cieslik M, Wang P, Birrer MJ, Paulovich AG. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer. Cell 186(16):3476-3498.e35, 2023. e-Pub 2023. PMID: 37541199.
7. Ferri-Borgogno S, Zhu Y, Sheng J, Burks JK, Gomez JA, Wong KK, Wong STC, Mok SC. Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors. Cancer Res 83(9):1503-1516, 2023. e-Pub 2023. PMID: 36787106.
8. Khlebus E, Vuttaradhi VK, Welte T, Khurana N, Celestino J, Beird HC, Gumbs C, Little L, Legarreta AF, Fellman BM, Nguyen T, Lawson B, Ferri-Borgogno S, Mok SC, Broaddus RR, Gershenson DM, Futreal PA, Hillman RT. Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors. Mol Cancer Res 21(5):483-494, 2023. e-Pub 2023. PMID: 37068116.
9. Osann K, Wenzel L, McKinney C, Wagner L, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Birrer M. Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors. Gynecol Oncol 171:151-158, 2023. e-Pub 2023. PMID: 36905875.
10. Zhang L, Au-Yeung CL, Huang C, Yeung TL, Ferri-Borgogno S, Lawson BC, Kwan SY, Yin Z, Wong ST, Thomas V, Lu KH, Yip KP, Sham JSK, Mok SC. Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes. J Exp Clin Cancer Res 41(1):242, 2022. e-Pub 2022. PMID: 35953818.
11. Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst 113(10):1369-1378, 2021. e-Pub 2021. PMID: 33729494.
12. Chung TKH, Doran G, Cheung TH, Yim SF, Yu MY, Worley MJ, Elias KM, Thorner AR, Pedamallu CS, Ojesina AI, Lau KM, Ducar MD, Wong RRY, Wang VW, Nag A, Wollison BM, Dalgarno A, Lee JHS, Yeung SY, Wong L, Horowitz NS, Davis MR, Leung SA, Mu Y, Mok SC, Chan PKS, Lawrence MS, Crum CP, Chiu RWK, Berkowitz RS, Wong YF. Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel) 13(13), 2021. e-Pub 2021. PMID: 34203201.
13. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 6(7), 2021. e-Pub 2021. PMID: 33793425.
14. Zhu Y, Ferri-Borgogno S, Sheng J, Yeung TL, Burks JK, Cappello P, Jazaeri AA, Kim JH, Han GH, Birrer MJ, Mok SC, Wong STC. SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Cancers (Basel) 13(8), 2021. e-Pub 2021. PMID: 33917869.
15. Shang N, Lee JTY, Huang T, Wang C, Lee TL, Mok SC, Zhao H, Chan WY. Disabled-2: a positive regulator of the early differentiation of myoblasts. Cell Tissue Res 381(3):493-508, 2020. e-Pub 2020. PMID: 32607799.
16. Hu W, Zhang L, Ferri-Borgogno S, Kwan SY, Lewis KE, Cun HT, Yeung TL, Soliman PT, Tarapore RS, Allen JE, Guan X, Lu KH, Mok SC, Au-Yeung CL. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers (Basel) 12(9), 2020. e-Pub 2020. PMID: 32867127.
17. Au-Yeung CL, Yeung TL, Achreja A, Zhao H, Yip KP, Kwan SY, Onstad M, Sheng J, Zhu Y, Baluya DL, Co NN, Rynne-Vidal A, Schmandt R, Anderson ML, Lu KH, Wong STC, Nagrath D, Mok SC. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nat Commun 11(1):3546, 2020. e-Pub 2020. PMID: 32669559.
18. Colvin EK, Howell VM, Mok SC, Samimi G, Vafaee F. Expression of lncRNAs in cancer-associated fibroblasts linked to patient survival in ovarian cancer. Cancer Sci 111(5):1805-1817, 2020. e-Pub 2020. PMID: 32058624.
19. Schwede M, Waldron L, Mok SC, Wei W, Basunia A, Merritt MA, Mitsiades CS, Parmigiani G, Harrington DP, Quackenbush J, Birrer MJ, Culhane AC. The impact of stroma admixture on molecular subtypes and prognostic gene signatures in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 29(2):509-519, 2020. e-Pub 2020. PMID: 31871106.
20. Kwan SY, Au-Yeung CL, Yeung TL, Rynne-Vidal A, Wong KK, Risinger JI, Lin HK, Schmandt RE, Yates MS, Mok SC, Lu KH. Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. Cancers (Basel) 12(1), 2020. e-Pub 2020. PMID: 31906456.
21. Yeung TL, Leung CS, Yip KP, Sheng J, Vien L, Bover LC, Birrer MJ, Wong STC, Mok SC. Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer. Clin Cancer Res 25(21):6417-6428, 2019. e-Pub 2019. PMID: 31332047.
22. Osmanbeyoglu HU, Shimizu F, Rynne-Vidal A, Alonso-Curbelo D, Chen HA, Wen HY, Yeung TL, Jelinic P, Razavi P, Lowe SW, Mok SC, Chiosis G, Levine DA, Leslie CS. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. Nat Commun 10(1):4369, 2019. e-Pub 2019. PMID: 31554806.
23. Hinchcliff E, Paquette C, Roszik J, Kelting S, Stoler MH, Mok SC, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri A. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunol Immunother 68(9):1515-1526, 2019. e-Pub 2019. PMID: 31515669.
24. Yeung TL, Tsai CC, Leung CS, Au Yeung CL, Thompson MS, Lu KH, Freedman RS, Birrer MJ, Wong KK, Mok SC. ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. Cancers (Basel) 10(12), 2018. e-Pub 2018. PMID: 30469497.
25. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 3(11), 2018. e-Pub 2018. PMID: 29889660.
26. Yeung TL, Sheng J, Leung CS, Li F, Kim J, Ho SY, Matzuk MM, Lu KH, Wong STC, Mok SC. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer. J Natl Cancer Inst. e-Pub 2018. PMID: 29860390.
27. Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest 128(2):589-606, 2018. e-Pub 2018. PMID: 29251630.
28. Vafaee F, Colvin EK, Mok SC, Howell VM, Samimi G. Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis. Sci Rep 7(1):10374, 2017. e-Pub 2017. PMID: 28871211.
29. Ma WG, Chou AS, Mok SCM, Ziganshin BA, Charilaou P, Zafar MA, Sieller RS, Tranquilli M, Rizzo JA, Elefteriades JA. Positive family history of aortic dissection dramatically increases dissection risk in family members. Int J Cardiol 240:132-137, 2017. e-Pub 2017. PMID: 28502736.
30. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 2(16). e-Pub 2017. PMID: 28814667.
31. Rynne-Vidal A, Au-Yeung CL, Jiménez-Heffernan JA, Pérez-Lozano ML, Cremades-Jimeno L, Bárcena C, Cristóbal-García I, Fernández-Chacón C, Yeung TL, Mok SC, Sandoval P, López-Cabrera M. Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. J Pathol 242(2):140-151, 2017. e-Pub 2017. PMID: 28247413.
32. Yeung TL, Leung CS, Wong KK, Gutierrez-Hartmann A, Kwong J, Gershenson DM, Mok SC. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget 8(10):16951-16963, 2017. e-Pub 2017. PMID: 28199976.
33. Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm G, Yuan Y, Mok SC, Broaddus RJ, Lu K, Yates MS. Immune microenvironment in microsatellite instable endometrial cancers: Hereditary or sporadic origin matters. Clin Cancer Res. e-Pub 2017. PMID: 28264871.
34. Chou AS, Ma WG, Mok SC, Ziganshin BA, Peterss S, Rizzo JA, Tranquilli M, Elefteriades JA. Do Familial Aortic Dissections Tend to Occur at the Same Age?. Ann Thorac Surg 103(2):546-550, 2017. e-Pub 2017. PMID: 27570161.
35. Mok SC, Ma WG, Mansour A, Charilaou P, Chou AS, Peterss S, Tranquilli M, Ziganshin BA, Elefteriades JA. Twenty-five year outcomes following composite graft aortic root replacement. J Card Surg 32(2):99-109, 2017. e-Pub 2017. PMID: 27966257.
36. Lo CM, Lo JC, Sato PY, Yeung TL, Mok SC, Yip KP. Monitoring of ovarian cancer cell invasion in real time with frequency-dependent impedance measurement. Am J Physiol Cell Physiol 311(6):ajpcell.00211.2016, 2016. e-Pub 2016. PMID: 27784677.
37. Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath D. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab 24(5):685-700, 2016. e-Pub 2016. PMID: 27829138.
38. Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, Schmandt R, Lu KH, Mok SC. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 7:11150, 2016. e-Pub 2016. PMID: 27021436.
39. Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget 6(42):44551-62, 2015. e-Pub 2015. PMID: 26575166.
40. Qiu MT, Fan Q, Zhu Z, Kwan SY, Chen L, Chen JH, Ying ZL, Zhou Y, Gu W, Wang LH, Cheng WW, Zeng J, Wan XP, Mok SC, Wong KK, Bao W. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1. Oncotarget 6(31):31702-20, 2015. e-Pub 2015. PMID: 26397136.
41. Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer 15:356, 2015. e-Pub 2015. PMID: 25939769.
42. Co NN, Iglesias D, Celestino J, Kwan SY, Mok SC, Schmandt R, Lu KH. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. Cancer 120(22):3457-68, 2014. e-Pub 2014. PMID: 25042259.
43. Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signaling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun 5:5092, 2014. e-Pub 2014. PMID: 25277212.
44. Yeung TL, Leung CS, Mok SC. CAF reprogramming inhibits ovarian cancer progression. Cell Cycle 13(24):0, 2014. e-Pub 2014. PMID: 25483059.
45. Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 231(4):449-56, 2013. e-Pub 2013. PMID: 24549645.
46. Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest 123(10):4435-48, 2013. e-Pub 2013. PMID: 24018557.
47. Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer?. Gynecol Oncol 130(3):565-9, 2013. e-Pub 2013. PMID: 23800698.
48. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res 73(16):5016-5028, 2013. e-Pub 2013. PMID: 23824740.
49. Mok SC, Teh AH, Saito JA, Najimudin N, Alam M. Crystal structure of a compact alpha-amylase from Geobacillus thermoleovorans. Enzyme Microb Technol 53(1):46-54, 2013. e-Pub 2013. PMID: 23683704.
50. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer. Clin Cancer Res 19(4):809-20, 2013. e-Pub 2013. PMID: 23344261.
51. Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM, Wong KK. PAX2 Expression in Ovarian Cancer. Int J Mol Sci 14(3):6090-105, 2013. e-Pub 2013. PMID: 23502471.
52. Merritt MA, Bentink S, Schwede M, Iwanicki MP, Quackenbush J, Woo T, Agoston ES, Reinhardt F, Crum CP, Berkowitz RS, Mok SC, Witt AE, Jones MA, Wang B, Ince TA. Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes. PLoS One 8(11):e80314, 2013. e-Pub 2013. PMID: 24303006.
53. Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, Woodward WA, Lu K, Salimian B, Nagrath D, Klopp AH. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One 8(12):e81859, 2013. e-Pub 2013. PMID: 24312594.
54. Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, Chan LK, Yu MY, Kwong J, Doran G, Barroilhet LM, Ng AS, Wong RR, Wang VW, Mok SC, Smith DI, Berkowitz RS, Wong YF. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer 130(5):1036-45, 2012. e-Pub 2012. PMID: 21400511.
55. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One 7(1):e29079, 2012. e-Pub 2012. PMID: 22272227.
56. King ER, Zu Z, Tsang YT, Deavers MT, Malpica A, Mok SC, Gershenson DM, Wong KK. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 123(1):13-8, 2011. e-Pub 2011. PMID: 21726895.
57. King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer. Am J Surg Pathol 35(6):904-12, 2011. e-Pub 2011. PMID: 21451362.
58. Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 13(5):393-405, 2011. e-Pub 2011. PMID: 21532880.
59. Gao Z, Xu X, McClane B, Zeng Q, Litkouhi B, Welch WR, Berkowitz RS, Mok SC, Garner EI. C-Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin. Clin Cancer Res 17(5):1065-74, 2011. e-Pub 2011. PMID: 21123456.
60. Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH. Microscopic and early stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila) 4(3):463-70, 2011. e-Pub 2011. PMID: 21278312.
61. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 6(7):e21121, 2011. e-Pub 2011. PMID: 21754983.
62. Young JL, Koon EC, Kwong J, Welch WR, Muto MG, Berkowitz RS, Mok SC. Differential hRad17 expression by histologic subtype of ovarian cancer. J Ovarian Res 4(1):6, 2011. e-Pub 2011. PMID: 21450056.
63. Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol 119(1):114-20, 2010. e-Pub 2010. PMID: 20619446.
64. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM. BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas. Am J Pathol 177(4):1611-7, 2010. e-Pub 2010. PMID: 20802181.
65. Zhang L, Wang D, Jiang W, Edwards D, Qiu W, Barroihet LM, Rho JH, Jin L, Seethappan V, Vitonis A, Wang J, Mok SC, Crum C, Cramer DW, Ye B. Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium. Reprod Biol Endocrinol 8(1):74. e-Pub 2010. PMID: 20576130.
66. Chan WY, Xia CL, Yew DT, Zhao H, Mok SC. Expression of Dab2, a Tumor Suppressor, in the Human Fetal Hippocampus and Neocortex. Neuroembriology and Aging 5:182-190. e-Pub 2010.
67. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16(6):521-32, 2009. e-Pub 2009. PMID: 19962670.
68. Thompson MS, Mok SC. Immunopathogenesis of ovarian cancer. Minerva Med 100(5):357-70, 2009. e-Pub 2009. PMID: 19910889.
69. Alper O, Stetler-Stevenson WG, Harris LN, Leitner WW, Ozdemirli M, Hartmann D, Raffeld M, Abu-Asab M, Byers S, Zhuang Z, Oldfield EH, Tong Y, Bergmann-Leitner E, Criss WE, Nagasaki K, Mok SC, Cramer DW, Karaveli FS, Goldbach-Mansky R, Leo P, Stromberg K, Weil RJ. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci 100(9):1748-56, 2009. e-Pub 2009. PMID: 19594548.
70. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 22(9):1243-50, 2009. e-Pub 2009. PMID: 19525924.
71. Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 11(6):529-41, 2009. e-Pub 2009. PMID: 19484142.
72. Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, Yu MY, To KF, Mok SC, Wang VW, Li C, Cheung AY, Doran G, Birrer MJ, Smith DI, Wong YF. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 124(6):1358-65, 2009. e-Pub 2009. PMID: 19065659.
73. Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K. Aberrant promoter methylation of sparc in ovarian cancer. Neoplasia 11(2):126-35, 2009. e-Pub 2009. PMID: 19177197.
74. Nevadunsky NS, Barbieri JS, Kwong J, Merritt MA, Welch WR, Berkowitz RS, Mok SC. RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecol Oncol 112(2):325-30, 2009. e-Pub 2009. PMID: 18937968.
75. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2642-2650, 2008. e-Pub 2008. PMID: 19092150.
76. Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, Berkowitz RS, Mok SC. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res 14(23):7667-73, 2008. e-Pub 2008. PMID: 19047092.
77. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 10(9):964-72, 2008. e-Pub 2008. PMID: 18714397.
78. Nagymanyoki Z, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Immune cell profiling in intraplacental and postmolar choriocarcinomas. J Reprod Med 53(8):558-64, 2008. e-Pub 2008. PMID: 18773618.
79. Nagymanyoki Z, Growdon WB, Sarno J, Callahan MJ, Parast MM, Fulop V, Mok SC, Horowitz N, Berkowitz RS. Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med 53(8):589-94, 2008. e-Pub 2008. PMID: 18773623.
80. Aponte M, Jiang W, Lakkis M, Li MJ, Edwards D, Albitar L, Vitonis A, Mok SC, Cramer DW, Ye B. Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res 68(14):5839-48, 2008. e-Pub 2008. PMID: 18632638.
81. Nagymanyoki Z, Butler MO, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Antigen-specific T cell immune response detected by skewed T cell receptor usage in normal placenta and complete molar pregnancy. J Reprod Med 53(7):528-34, 2008. e-Pub 2008. PMID: 18720929.
82. Wang D, Zhao Z, Caperell-Grant A, Yang G, Mok SC, Liu J, Bigsby RM, Xu Y. S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol Cancer Ther 7(7):1993-2002, 2008. e-Pub 2008. PMID: 18645009.
83. Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol 109(2):234-9, 2008. e-Pub 2008. PMID: 18331757.
84. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 14(3):764-71, 2008. e-Pub 2008. PMID: 18245537.
85. Nagymanyoki Z, Callahan MJ, Parast MM, Berkowitz RS, Mok SC, Fulop V. Overexpression of laminin receptor 1 on decidual cells in partial and complete mole. Gynecol Oncol 108(1):121-5, 2008. e-Pub 2008. PMID: 17928039.
86. Cheung KK, Mok SC, Rezaie P, Chan WY. Dynamic expression of Dab2 in the mouse embryonic central nervous system. BMC Dev Biol 8:76, 2008. e-Pub 2008. PMID: 18680569.
87. Cheung KK, Mok SC, Zhao H, Rezaie P, Chan WY. Inhibition of Dab2 expression with antisense oligodeoxynucleotides in mouse embryo. Neuroembryol Aging:89-99, 2008. e-Pub 2008.
88. Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 18(5):976-84. e-Pub 2007. PMID: 18021219.
89. Nagymanyoki Z, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Immune cell profiling in normal pregnancy, partial and complete molar pregnancy. Gynecol Oncol 107(2):292-7. e-Pub 2007. PMID: 17878059.
90. Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 106(2):311-7, 2007. e-Pub 2007. PMID: 17532031.
91. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25(16):2281-7, 2007. e-Pub 2007. PMID: 17538174.
92. Litkouhi B, Kwong J, Lo CM, Smedley JG, McClane BA, Aponte M, Gao Z, Sarno JL, Hinners J, Welch WR, Berkowitz RS, Mok SC, Garner EI. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9(4):304-14, 2007. e-Pub 2007. PMID: 17460774.
93. Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia 9(1):23-35, 2007. e-Pub 2007. PMID: 17325741.
94. Nishimura S, Tsuda H, Ito K, Jobo T, Yaegashi N, Inoue T, Sudo T, Berkowitz RS, Mok SC. Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. Hum Pathol 38(1):134-9, 2007. e-Pub 2007. PMID: 16996567.
95. Park DC, Yeo SG, Shin EY, Mok SC, Kim DH. Clusterin confers paclitaxel resistance in cervical cancer. Gynecol Oncol 103(3):996-1000, 2006. e-Pub 2006. PMID: 16890274.
96. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, Mok SC, Brady J, Bonome T, Birrer MJ. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 66(17):8404-12, 2006. e-Pub 2006. PMID: 16951150.
97. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, Mok SC, Xu Y. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 66(16):7983-90, 2006. e-Pub 2006. PMID: 16912173.
98. Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC, Ng SW. Selenium binding protein 1 in ovarian cancer. Int J Cancer 118(10):2433-40, 2006. e-Pub 2006. PMID: 16380993.
99. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC. PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 101(1):71-5, 2006. e-Pub 2006. PMID: 16290000.
100. Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, Mok SC. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8(4):268-78, 2006. e-Pub 2006. PMID: 16756719.
101. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12(2):432-41, 2006. e-Pub 2006. PMID: 16428483.
102. Hashiguchi Y, Tsuda H, Bandera CA, Nishimura S, Inoue T, Kawamura N, Berkowitz RS, Mok SC. Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer. Med Oncol 23(2):205-12, 2006. e-Pub 2006. PMID: 16720920.
103. Feinberg BB, Jack RM, Mok SC, Anderson DJ. Low erythrocyte complement receptor type 1 (CR1, CD35) expression in preeclamptic gestations. Am J Reprod Immunol 54(6):352-7, 2005. e-Pub 2005. PMID: 16305660.
104. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65(22):10602-12, 2005. e-Pub 2005. PMID: 16288054.
105. Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res 11(21):7651-7, 2005. e-Pub 2005. PMID: 16278384.
106. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-77, 2005. e-Pub 2005. PMID: 16061277.
107. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 11(19 Pt 1):6880-8, 2005. e-Pub 2005. PMID: 16203778.
108. Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, Berkowitz R, Mok SC, Bandera CA. Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet 161(2):170-3, 2005. e-Pub 2005. PMID: 16102589.
109. Qin S, Ferdinand AS, Richie JP, O'Leary MP, Mok SC, Liu BC. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 5(12):3183-92, 2005. e-Pub 2005. PMID: 16035113.
110. Mok SC, Savage I. Why has safety improved at rail-highway grade crossings?. Risk Anal 25(4):867-81, 2005. e-Pub 2005. PMID: 16268935.
111. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65(6):2162-9, 2005. e-Pub 2005. PMID: 15781627.
112. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 96(1):77-83, 2005. e-Pub 2005. PMID: 15589584.
113. Kwong J, Lo KW, Chow LS, To KF, Choy KW, Chan FL, Mok SC, Huang DP. Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. Neoplasia 7(1):67-74, 2005. e-Pub 2005. PMID: 15720818.
114. Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, Wong WH, Rao PH, Lau CC, Berkowitz RS, Wong KK, Mok SC. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet 155(2):97-107, 2004. e-Pub 2004. PMID: 15571795.
115. Zhou X, Mok SC, Chen Z, Li Y, Wong DT. Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Hum Genet 115(4):327-30, 2004. e-Pub 2004. PMID: 15290239.
116. Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS, Ng SW. Characterization of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 91(4):725-31, 2004. e-Pub 2004. PMID: 15305183.
117. Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, Ng TB, Chung TK, Mok SC. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 211(2):227-34, 2004. e-Pub 2004. PMID: 15219946.
118. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 10(10):3474-8, 2004. e-Pub 2004. PMID: 15161704.
119. Zhou X, Li C, Mok SC, Chen Z, Wong DT. Whole genome loss of heterozygosity profiling on oral squamous cell carcinoma by high-density single nucleotide polymorphic allele (SNP) array. Cancer Genet Cytogenet 151(1):82-4, 2004. e-Pub 2004. PMID: 15120915.
120. Tsuda H, Bandera CA, Birrer MJ, Hashiguchi Y, Berkowitz RS, Mok SC. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 67(3-4):291-9, 2004. e-Pub 2004. PMID: 15557791.
121. Zheng Y, Xu Y, Ye B, Lei J, Weinstein MH, O'Leary MP, Richie JP, Mok SC, Liu BC. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98(12):2576-82, 2003. e-Pub 2003. PMID: 14669276.
122. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 9(13):4811-8, 2003. e-Pub 2003. PMID: 14581352.
123. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9(13):4782-91, 2003. e-Pub 2003. PMID: 14581349.
124. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9(8):2904-11, 2003. e-Pub 2003. PMID: 12912935.
125. Ho SM, Lau KM, Mok SC, Syed V. Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 22(27):4243-56, 2003. e-Pub 2003. PMID: 12833147.
126. Bandera CA, Tsui HW, Mok SC, Tsui FW. Expression of cytokines and receptors in normal, immortalized, and malignant ovarian epithelial cell lines. Anticancer Res 23(4):3151-7, 2003. e-Pub 2003. PMID: 12926048.
127. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9(5):568-74, 2003. e-Pub 2003. PMID: 12692539.
128. Batorfi J, Fulop V, Kim JH, Genest DR, Doszpod J, Mok SC, Berkowitz RS. Osteopontin is down-regulated in hydatidiform mole. Gynecol Oncol 89(1):134-9, 2003. e-Pub 2003. PMID: 12694667.
129. Batorfi J, Ye B, Mok SC, Cseh I, Berkowitz RS, Fulop V. Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells. Gynecol Oncol 88(3):424-8, 2003. e-Pub 2003. PMID: 12648597.
130. Batorfi J, Fulop V, Kim JH, Genest DR, Doszpod J, Mod SC, Berkowitz RS. Osteopontin is down-regulated in hydatidiform mole. Gynecol Oncol 89:134-139, 2003. e-Pub 2003.
131. Batorfi J, YE B, Mok SC, Cseh I, Berkowitz RS, Fulop V. Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells. Gynecol Oncol 88:424-428, 2003. e-Pub 2003.
132. Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randrianarison V, Brodie S, Salstrom J, Rasmussen TP, Klimke A, Marrese C, Marahrens Y, Deng CX, Feunteun J, Livingston DM. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 111(3):393-405, 2002. e-Pub 2002. PMID: 12419249.
133. Bourdon V, Naef F, Rao PH, Reuter V, Mok SC, Bosl GJ, Koul S, Murty VV, Kucherlapati RS, Chaganti RS. Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes. Cancer Res 62(21):6218-23, 2002. e-Pub 2002. PMID: 12414650.
134. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA, Gazdar AF. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8(11):3324-31, 2002. e-Pub 2002. PMID: 12429618.
135. Kleeff J, Huang Y, Mok SC, Zimmermann A, Friess H, Buchler MW. Down-regulation of DOC-2 in colorectal cancer points to its role as a tumor suppressor in this malignancy. Dis Colon Rectum 45(9):1242-8, 2002. e-Pub 2002. PMID: 12352243.
136. Huang KC, Rao PH, Lau CC, Heard E, Ng SK, Brown C, Mok SC, Berkowitz RS, Ng SW. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther 1(10):769-76, 2002. e-Pub 2002. PMID: 12492109.
137. Garner EI, Stokes EE, Berkowitz RS, Mok SC, Cramer DW. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res 62(11):3058-62, 2002. e-Pub 2002. PMID: 12036914.
138. Tsui HW, Hasselblatt K, Martin A, Mok SC, Tsui FW. Molecular mechanisms underlying SHP-1 gene expression. Eur J Biochem 269(12):3057-64, 2002. e-Pub 2002. PMID: 12071971.
139. Syed V, Ulinski G, Mok SC, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 94(8):617-29, 2002. e-Pub 2002. PMID: 11959895.
140. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13):1671-9, 2002. e-Pub 2002. PMID: 11926891.
141. Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, Agrez MV, Mok S, Baker MS. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 23(2):237-44, 2002. e-Pub 2002. PMID: 11872628.
142. Rao PH, Harris CP, Yan Lu X, Li XN, Mok SC, Lau CC. Multicolor spectral karyotyping of serous ovarian adenocarcinoma. Genes Chromosomes Cancer 33(2):123-32, 2002. e-Pub 2002. PMID: 11793438.
143. Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randianarison V, et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 111:393-405, 2002. e-Pub 2002.
144. Tsui HW, Hasselblatt K, Martin A, Mok SC, Tsui FW. Molecular mechanisms underlying SHP-1 gene expression. Eur J Biochem 269:3057-3064, 2002. e-Pub 2002.
145. Kleef J, Huang Y, Mok SC, Zimmerman A, Friess H, Buchler MW. Down-regulation of DOC-2 in colorectal cancer points to its role as a tumor suppressor in this malignancy. Dis Colon Rectum 45:1242-1248, 2002. e-Pub 2002.
146. Bouron V, Naef F, Rao PH, Reuter V, Mok SC, Bosl GH, Koul S, VVVS M, Kucherlapati RS, Chaganti RSK. Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identified two novel amplified and overexpressed genes. Cancer Res 62:6218-6223, 2002. e-Pub 2002.
147. Mok SC, Skates SJ, Berkowitz RS, Cramer DW. Osteopontin as a biomarker for ovarian cancer. JAMA 287:3208-3210, 2002. e-Pub 2002.
148. Wang SC, Makino K, Xia W, Kim JS, Im SA, Peng H, Mok SC, Singletary SE, Hung MC. DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene 20(47):6960-4, 2001. e-Pub 2001. PMID: 11687976.
149. Ortiz BH, Ailawadi M, Colitti C, Muto MG, Deavers M, Silva EG, Berkowitz RS, Mok SC, Gershenson DM. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 61(19):7264-7, 2001. e-Pub 2001. PMID: 11585764.
150. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 93(19):1458-64, 2001. e-Pub 2001. PMID: 11584061.
151. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61(18):6768-76, 2001. e-Pub 2001. PMID: 11559549.
152. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, Mok SC. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159(2):609-22, 2001. e-Pub 2001. PMID: 11485919.
153. Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC. K-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 20(3):244-51, 2001. e-Pub 2001. PMID: 11444200.
154. Huang Y, Friess H, Kleeff J, Esposito I, Zhu Z, Liu S, Mok SC, Zimmermann A, Buchler MW. Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis. Lab Invest 81(6):863-73, 2001. e-Pub 2001. PMID: 11406647.
155. Wang VW, Bell DA, Berkowitz RS, Mok SC. Whole genome amplification and high-throughput allelotyping identified five distinct deletion regions on chromosomes 5 and 6 in microdissected early-stage ovarian tumors. Cancer Res 61(10):4169-74, 2001. e-Pub 2001. PMID: 11358841.
156. Schwartz BM, Hong G, Morrison BH, Wu W, Baudhuin LM, Xiao YJ, Mok SC, Xu Y. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol 81(2):291-300, 2001. e-Pub 2001. PMID: 11330965.
157. Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30(3):670-5, 2001. e-Pub 2001. PMID: 11252802.
158. Arnold JM, Mok SC, Purdie D, Chenevix-Trench G. Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas. Br J Cancer 84(3):352-9, 2001. e-Pub 2001. PMID: 11161400.
159. Wang SC, Makino K, Xia W, Kim JS, IM SA, Peng H, Mok SC, Singletary SE, Hung MC. DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene 20:6960=6964, 2001. e-Pub 2001.
160. Okubo T, Mok SC, Chen S. Regulation of aromatase expression in human ovarian surface epithelial cells. J Clin Endocrinol Metab 85(12):4889-99, 2000. e-Pub 2000. PMID: 11134158.
161. Rauh-Adelmann C, Lau KM, Sabeti N, Long JP, Mok SC, Ho SM. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Mol Carcinog 28(4):236-46, 2000. e-Pub 2000. PMID: 10972993.
162. Huang LW, Garrett AP, Schorge JO, Muto MG, Bell DA, Welch WR, Berkowitz RS, Mok SC. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. Am J Clin Pathol 114(1):93-9, 2000. e-Pub 2000. PMID: 10884804.
163. Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS, Mok SC. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 77(3):369-76, 2000. e-Pub 2000. PMID: 10831344.
164. Tuncer ZS, Vegh GL, Fulop V, Genest DR, Mok SC, Berkowitz RS. Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecol Oncol 77(3):389-93, 2000. e-Pub 2000. PMID: 10831347.
165. Ng SW, Yiu GK, Liu Y, Huang LW, Palnati M, Jun SH, Berkowitz RS, Mok SC. Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene 19(15):1885-90, 2000. e-Pub 2000. PMID: 10773878.
166. Garrett AP, Ng SW, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum. Gynecol Oncol 77(1):105-11, 2000. e-Pub 2000. PMID: 10739698.
167. Schorge JO, Muto MG, Lee SJ, Huang LW, Welch WR, Bell DA, Keung EZ, Berkowitz RS, Mok SC. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 60(5):1361-4, 2000. e-Pub 2000. PMID: 10728699.
168. Schorge JO, Miller YB, Qi LJ, Muto MG, Welch WR, Berkowitz RS, Mok SC. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol 76(3):369-72, 2000. e-Pub 2000. PMID: 10684712.
169. Huang LW, Garrett AP, Muto MG, Colitti CV, Bell DA, Welch WR, Berkowitz RS, Mok SC. Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum. Hum Pathol 31(3):367-73, 2000. e-Pub 2000. PMID: 10746681.
170. Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, Berkowitz RS, Mok SC. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 156(2):409-17, 2000. e-Pub 2000. PMID: 10666369.
171. Vegh GL, Fulop V, Liu Y, Ng SW, Tuncer ZS, Genest DR, Paldi-Haris P, Foldi J, Mok SC, Berkowitz RS. Differential gene expression pattern between normal human trophoblast and choriocarcinoma cell lines: downregulation of heat shock protein-27 in choriocarcinoma in vitro and in vivo. Gynecol Oncol 75(3):391-6, 1999. e-Pub 1999. PMID: 10600295.
172. Vegh GL, Selcuk Tuncer Z, Fulop V, Genest DR, Mok SC, Berkowitz RS. Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta. Gynecol Oncol 75(2):248-53, 1999. e-Pub 1999. PMID: 10525381.
173. Imyanitov EN, Birrell GW, Filippovich I, Sorokina N, Arnold J, Mould MA, Wright K, Walsh M, Mok SC, Lavin MF, Chenevix-Trench G, Khanna KK. Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene 18(32):4640-2, 1999. e-Pub 1999. PMID: 10467409.
174. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A 96(10):5722-7, 1999. e-Pub 1999. PMID: 10318951.
175. Ng SW, Liu Y, Hasselblatt KT, Mok SC, Berkowitz RS. A new human topoisomerase III that interacts with SGS1 protein. Nucleic Acids Res 27(4):993-1000, 1999. e-Pub 1999. PMID: 9927731.
176. Schorge JO, Mok SC. Understanding the pathogenesis of primary peritoneal carcinoma: involvement of the BRCA1 and p53 genes. Hum Pathol 30(2):115-6, 1999. e-Pub 1999. PMID: 10029436.
177. Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 93(1):34-7, 1999. e-Pub 1999. PMID: 9916952.
178. Iyengar TD, Ng S, Lau CC, Welch WR, Bell DA, Berkowitz RS, Mok SC. Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors. Oncogene 18(1):257-62, 1999. e-Pub 1999. PMID: 9926941.
179. Bandera CA, Muto MG, Schorge JO, Berkowitz RS, Rubin SC, Mok SC. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 92(4 Pt 1):596-600, 1998. e-Pub 1998. PMID: 9764635.
180. Fulop V, Colitti CV, Genest D, Berkowitz RS, Yiu GK, Ng SW, Szepesi J, Mok SC. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene 17(4):419-24, 1998. e-Pub 1998. PMID: 9696034.
181. Bandera CA, Muto MG, Welch WR, Berkowitz RS, Mok SC. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. Oncogene 16(26):3455-9, 1998. e-Pub 1998. PMID: 9692553.
182. Schorge JO, Muto MG, Welch WR, Bandera CA, Rubin SC, Bell DA, Berkowitz RS, Mok SC. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 90(11):841-5, 1998. e-Pub 1998. PMID: 9625172.
183. Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 58(11):2328-30, 1998. e-Pub 1998. PMID: 9622067.
184. Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 16(18):2381-7, 1998. e-Pub 1998. PMID: 9620555.
185. Quayle AJ, Porter EM, Nussbaum AA, Wang YM, Brabec C, Yip KP, Mok SC. Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am J Pathol 152(5):1247-58, 1998. e-Pub 1998. PMID: 9588893.
186. Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I, Berkowitz RS. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 43(2):101-10, 1998. e-Pub 1998. PMID: 9513871.
187. Fulop V, Mok SC, Genest DR, Gati I, Doszpod J, Berkowitz RS. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 43(2):119-27, 1998. e-Pub 1998. PMID: 9513873.
188. Colitti CV, Rodabaugh KJ, Welch WR, Berkowitz RS, Mok SC. A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas. Oncogene 16(4):555-9, 1998. e-Pub 1998. PMID: 9484846.
189. Edelson MI, Lau CC, Colitti CV, Welch WR, Bell DA, Berkowitz RS, Mok SC. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors. Oncogene 16(2):197-202, 1998. e-Pub 1998. PMID: 9464537.
190. Edelson MI, Scherer SW, Tsui LC, Welch WR, Bell DA, Berkowitz RS, Mok SC. Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas. Oncogene 14(24):2979-84, 1997. e-Pub 1997. PMID: 9205105.
191. Smith AC, Barry SE, Chiong AY, Hadzakis D, Kha SL, Mok SC, Sable DL. Inferior alveolar nerve damage following removal of mandibular third molar teeth. A prospective study using panoramic radiography. Aust Dent J 42(3):149-52, 1997. e-Pub 1997. PMID: 9241922.
192. Lu KH, Weitzel JN, Kodali S, Welch WR, Berkowitz RS, Mok SC. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. Cancer Res 57(3):387-90, 1997. e-Pub 1997. PMID: 9012461.
193. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 2(5):624-36, 1996. e-Pub 1996. PMID: 8898378.
194. Tangir J, Loughridge NS, Berkowitz RS, Muto MG, Bell DA, Welch WR, Mok SC. Frequent microsatellite instability in epithelial borderline ovarian tumors. Cancer Res 56(11):2501-5, 1996. e-Pub 1996. PMID: 8653685.
195. Wertheim I, Tangir J, Muto MG, Welch WR, Berkowitz RS, Chen WY, Mok SC. Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors. Oncogene 12(10):2147-53, 1996. e-Pub 1996. PMID: 8668340.
196. Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12(9):1895-901, 1996. e-Pub 1996. PMID: 8649850.
197. Muto MG, Cramer DW, Tangir J, Berkowitz R, Mok S. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 56(6):1250-2, 1996. e-Pub 1996. PMID: 8640808.
198. Tangir J, Muto MG, Berkowitz RS, Welch WR, Bell DA, Mok SC. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer. Oncogene 12(4):735-40, 1996. e-Pub 1996. PMID: 8632895.
199. Rodabaugh KJ, Biggs RB, Qureshi JA, Barrett AJ, Welch WR, Bell DA, Berkowitz RS, Mok SC. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene 11(7):1249-54, 1995. e-Pub 1995. PMID: 7478544.
200. Tsao SW, Mok SC, Fey EG, Fletcher JA, Wan TS, Chew EC, Muto MG, Knapp RC, Berkowitz RS. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 218(2):499-507, 1995. e-Pub 1995. PMID: 7796885.
201. Mok SC, Kwok TT, Berkowitz RS, Barrett AJ, Tsui FW. Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer. Gynecol Oncol 57(3):299-303, 1995. e-Pub 1995. PMID: 7774833.
202. Rodabaugh KJ, Blanchard G, Welch WR, Bell DA, Berkowitz RS, Mok SC. Detailed deletion mapping of chromosome 6q in borderline epithelial ovarian tumors. Cancer Res 55(10):2169-72, 1995. e-Pub 1995. PMID: 7743519.
203. Muto MG, Welch WR, Mok SC, Bandera CA, Fishbaugh PM, Tsao SW, Lau CC, Goodman HM, Knapp RC, Berkowitz RS. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 55(3):490-2, 1995. e-Pub 1995. PMID: 7834614.
204. Lau CC, Mok SC, Kelley A, Cramer D. Detection of a RsaI polymorphism within the human galactokinase gene (GK2) by PCR-SSCP. Hum Mol Genet 3(10):1916, 1994. e-Pub 1994. PMID: 7849734.
205. Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 86(20):1549-51, 1994. e-Pub 1994. PMID: 7932812.
206. Chan WY, Ng TB, Rong SH, Yeung HW, Mok SC. Antiproliferative and teratogenic activities of the bishemisuccinates of 7 alpha-hydroxycholesterol and 7 beta-hydroxycholesterol. Gen Pharmacol 25(4):767-72, 1994. e-Pub 1994. PMID: 7958740.
207. Steller MA, Mok SC, Yeh J, Fulop V, Anderson DJ, Berkowitz RS. Effects of cytokines on epidermal growth factor receptor expression by malignant trophoblast cells in vitro. J Reprod Med 39(3):209-16, 1994. e-Pub 1994. PMID: 8035376.
208. Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, Berkowitz RS. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 52(2):247-52, 1994. e-Pub 1994. PMID: 8314147.
209. Kwok TT, Mok SC, Menton-Brennan L. Up-regulation of a mutant form of P53 by doxorubicin in human squamous carcinoma cells. Cancer Res 54:2834-2836, 1994. e-Pub 1994.
210. Mok SC, Wong KK, Chan RWK, Tsao SW Knapp RC, Berkowitz RS, Lau CC. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gyn Oncology 52:247-252, 1994. e-Pub 1994.
211. Mok SC, Lo KW, Tsao SW. Direct cycle sequencing of mutated alleles detected by PCR single-strand conformation polymorphism analysis. Biotechniques 14(5):790-4, 1993. e-Pub 1993. PMID: 8512704.
212. Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao SW. Mutation of K-ras proto-oncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53(7):1489-92, 1993. e-Pub 1993. PMID: 8384077.
213. Tsao SW, Mok CH, Knapp RC, Oike K, Muto MG, Welch WR, Goodman HM, Sheets EE, Berkowitz RS, Lau CC. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol 48(1):5-10, 1993. e-Pub 1993. PMID: 8423021.
214. Tsui FWL, Tsui HW, Mok SC, Mlinaric I, Copeland NG, Gilbert DJ, Jenkins NA, Siminovitch KA. Molecular characterization and mapping of murine genes encoding three members of the stefin family of cysteine proteinase inhibitors. Genomics 15:507-514, 1993. e-Pub 1993.
215. Tsui HW, Mok SC, Martin A, Tsui JWL. Transcription analyses of the gene region that encodes human histidyl-RNA synthetase: Identification of a novel bidirectional regulatory element. Gene 131:201-208, 1993. e-Pub 1993.
216. Wong KK, Mok SC, Welsh JT, McClelland M, Tsao SW, Berkowitz RS. Identification of differentially expressed RNA from human ovarian carcinoma cells by arbitrarily primed PCR fingerprinting of total RNA. Int J Oncology 3:13-17, 1993. e-Pub 1993.
217. Mok CH, Tsao SW, Knapp RC, Fishbaugh PM, Lau CC. Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 52(18):5119-5122, 1992. e-Pub 1992. PMID: 1516069.
218. Lo KW, Mok SC, Chung G, Huang DP, Wong F, Chang M, Lee JCK, Tsao SW. Presence of p53 mutation in human cervical carcinomas associated with HPV-33. Anticancer Res 12:1989-1994, 1992. e-Pub 1992.
219. Lo KW, Mok SC, Huang DP, Liu YX, Coi PHK, Lee JCK, Tsao SW. Mutation of p53 gene in nasopharyngeal carcinomas, an infrequent event. Anticancer Res 12:1957-1964, 1992. e-Pub 1992.
220. Chew EC, Yeung AS, Chew SB, Mok SC, Liew CC. Immunogold localization of a nuclear protein at different stages of the cell cycle in normal and tumor cells. In Vivo 5(4):433-40, 1991. e-Pub 1991. PMID: 1810435.
221. Tsao SW, Mok SC, Oike K, Muto MG, Goodman HM, Sheets EE, Berkowitz RS, Knapp RC, Lau CC. Involvement of the p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors. Anticancer Res 11:1975-1982, 1991. e-Pub 1991.
222. Lo KW, Mok SC, Chung G, Huang DP, Wong F, Chan M, Lee JCK, Tsao SW. presence of p53 mutation in human cervical carcinomas associated with HPV-33. Anticancer Res 11:1875-1982, 1991. e-Pub 1991.
223. Chew EC, Yam GHF, Tsao SW, Mok SC, Hon JH, LI RSC, Ho TH, Tam JSL, Lee JCK. Establishment and characterization of a new squamous carcinoma cell line from tumor of the esophagus. Recent Advances in Cancer, Hong Kong:79-97, 1989. e-Pub 1989.
224. Chew EC, Mok SC, Wong WE, Jen LS, Riches DJ. Ultrastructural study on the invasion of the basal lamina of retinal inner limiting membrane by esophageal carcinoma cells. Anticancer Res 8:517-524, 1988. e-Pub 1988.
225. Chew EC, Mok SC, Tsao SW, Liu WK, Riches DJ. Scanning electron microscopic study of invasiveness between normal and neoplastic cells and fibroblasts in monolayer culture. Anticancer Res 8:257-289, 1988. e-Pub 1988.
226. Mok SC, Chew EC, Riches DJ, Lee JCK, Huang DP, Hadges C, Crofts TJ. Biological characteristics of a newly established human esophageal carcinoma cell line. Anticancer Res 7:409-416, 1987. e-Pub 1987.
227. Mok SC, Chew EC, Riches DJ. Interaction of melanoma cells and normal mouse skin fibroblasts in three dimensional collagen gels in vitro: TEM and SEM studies. Anticancer Res 6:995-1004, 1986. e-Pub 1986.

Invited Articles

1. Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. Am J Physiol Cell Physiol 309(7):ajpcell.00188.2015, 2015. e-Pub 2015. PMID: 26224579.
2. Lu KH, Yates MS, Mok SC. The monkey, the hen, and the mouse: Models to advance ovarian cancer chemoprevention. Cancer Prev Res (Phila) 2(9):773-5, 2009. e-Pub 2009. PMID: 19737981.
3. Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl) 4:27-40, 2008. e-Pub 2008. PMID: 19072449.
4. Ye B, Gagnon A, Mok SC. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev Proteomics 4(1):121-31, 2007. e-Pub 2007. PMID: 17288520.
5. Samimi G, Ozbun L, Johnson ME, Mok SC, Birrer MJ. Biomarkers of mucinous tumors of the ovary. Dis Markers 23(5-6):389-96, 2007. e-Pub 2007. PMID: 18057522.
6. Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 96:1-22, 2007. e-Pub 2007. PMID: 17161674.
7. Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23(5-6):367-76, 2007. e-Pub 2007. PMID: 18057520.
8. Fulop V, Mok SC, Berkowitz RS. Molecular biology of gestational trophoblastic neoplasia: a review. J Reprod Med 49(6):415-22, 2004. e-Pub 2004. PMID: 15283047.
9. Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, Cramer DW. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 20(2):53-70, 2004. e-Pub 2004. PMID: 15322314.
10. Bandera CA, Ye B, Mok SC. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 15(1):51-5, 2003. e-Pub 2003. PMID: 12544502.
11. Fulop V, Mod SC, Gati I, Berkowitz RS. Recent advances in molecular biology of gestational trophoblastic diseases. J Reprod Med 47:369-379, 2002. e-Pub 2002.
12. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 25(3):281-304, 1998. e-Pub 1998. PMID: 9633841.
13. Wong KK, Mok SC. Molecular genetics of ovarian cancer. Ovarian Cancer.
14. Mok SC, Wong KK, Lu K, Nagymanyoki Z. Molecular basis of gynecologic diseases. Molecular Pathology.

Review Articles

1. Ring, K, Mills, AM, Howitt, BE, Grisham, RN, Euscher, ED, Kim, HS, Klopp, AH, Kolin, DL, McCluggage, WG, Mirkovic, J, Park, K, Aoun, E, Awujo, C, Son, J, Mok, S, Ferri-Borgogno, S, Hong, DS, Hoang, L, Jazaeri, AA, How, JA, Lu, KH. Mesonephric-like adenocarcinoma of the female genital tract. Gynecologic oncology 197:57-65, 2025. e-Pub 2025. PMID: 40279981.
2. Zhang L, Kwan SY, Wong KK, Solaman PT, Lu KH, Mok SC. Pathogenesis and Clinical Management of Uterine Serous Carcinoma. Cancers (Basel) 12(3), 2020. e-Pub 2020. PMID: 32183290.
3. Lewis KE, Lu KH, Klimczak AM, Mok SC. Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision. Cancers (Basel) 10(2), 2018. e-Pub 2018. PMID: 29466291.
4. Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 35(7):816-26, 2016. e-Pub 2016. PMID: 25961926.
5. Yeung TL, Leung CS, Li F, Wong SS, Mok SC. Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules 6(1):3, 2016. e-Pub 2016. PMID: 26751490.
6. Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol 622:23-33, 2008. e-Pub 2008. PMID: 18546616.
7. Zhou X, Rao NP, Cole SW, Mok SC, Chen Z, Wong DT. Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays. Cancer Genet Cytogenet 159(1):53-7, 2005. e-Pub 2005. PMID: 15860358.
8. Feltmate CM, Mok SC. Whole-genome allelotyping using laser microdissected tissue. Methods Mol Biol 293:69-77, 2005. e-Pub 2005. PMID: 16028411.
9. Fulop V, Mok SC, Gati I, Berkowitz RS. Recent advances in molecular biology of gestational trophoblastic diseases. A review. J Reprod Med 47(5):369-79, 2002. e-Pub 2002. PMID: 12063875.

Other Articles

1. Chowdhury S, Wang, P, Mok SC, Ferri-Borgogno, S, Yang, P, Wang, W, Peng, J Learning directed acyclic graphs for ligands and receptors based on spatially resolved transcriptomic data of ovarian cancer. National Library of Medicine, 2025. PMID: 40062614.
2. Chowdhury, S, Kennedy, J, Ivey, RG, Murillo, OD, Hosseini, N, Song, X, Petralia, F, Calinawan, A, Savage, SR, Berry, AB, Reva, B, Özbek, U, Krek, A, Ma, W, da Veiga Leprevost, F, Ji, J, Yoo, S, Lin, CW, Voytovich, UJ, Huang, Y, Lee, SH, Bergan, L, Lorentzen, TD, Mesri, M, Rodriguez, H, Hoofnagle, AN, Herbert, ZT, Nesvizhskii, AI, Zhang, B, Whiteaker, J, Fenyö, D, McKerrow, W, Wang, JM, Schurer, S, Stathias, V, Chen, XS, Barcellos-Hoff, MH, Starr, TK, Winterhoff, B, Nelson, AC, Mok, S, Kaufmann, SH, Drescher, CW, Cieślik, M, Wang, P, Birrer, MJ, Paulovich, AG Erratum. Cell 187(4):1016, 2024. PMID: 38364782.
3. Han C, Leonardo TR, Romana-Souza B, Shi J, Keiser S, Yuan H, Altakriti M, Ranzer MJ, Ferri-Borgogno S, Mok SC, Koh TJ, Hong SJ, Chen L, DiPietro LA Microfibril-associated protein 5 and the regulation of skin scar formation, 2023. PMID: 37253753.
4. Hu W, Zhang L, Ferri-Borgogno S, Kwan SY, Lewis KE, Cun HT, Yeung TL, Soliman PT, Tarapore RS, Allen JE, Guan X, Lu KH, Mok SC, Au-Yeung CL Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436. Cancers (Basel) 13(4), 2021. PMID: 33557446.

Editorials

1. Mok SC. Letter from the New Editor-in-Chief. Cancers (Basel) 8(1), 2016. PMID: 26791308.

Abstracts

1. Tarapore RS, Vv P, Mok SC, Au Yeung C. Immuno-modulatory activity of Selective DRD2 Antagonist ONC201, an Imipridone, in Metastatic Endomettiral Cancer (mEC. Proceedings of the Annual American Association for Cancer Research(3982), 2020. e-Pub 2020.
2. Hu W, Zhang L, Ferri-Borgogno S. Novel imipridone ONC206 inhibits cell proliferation and indjces apoptis in uterine serous cancer through altering MAPK/AKT signaling network and metabolic reprogramming. Proceedings of the Annual American Association for Cancer Research, 2020. e-Pub 2020.
3. Osmanbeyoglu HU, Shimizu F, Rynne-Vidal A, Yeung TL, Jelinic P, Mok SC, Chiosis G, Levine DA, Leslie C. Chromatin-informed inference of transriptional programs in gynecologic and basal breast cancers. Proceedings of the 110th Annual Meeting of the American Association for Cancer Research(6030), 2019. e-Pub 2019.
4. Hinchcliff, E, Paquette C, Roszik J, Kelting S, Stoler M, Mok SC, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri A. The prognostic and biologic sifnificance of lymphocyte-specific protein tyrosine kinase expression in high grade serous ovarian cancer. Proceedings of the 110th Annual Meeting of the American Association for Cancer Research, 2019. e-Pub 2019.
5. Zhu Y, Yeung TL, Sheng J, Mok SC, Wong STC. An image informatics pipeline for imaging mass cytometry and its application to characterize and visualize the immune landscape in epithelial ovarian cancer patients with long term and short term survival [eropds. Proceedings of the 110th Annual Meeting of the American Association for Cancer Research, 2019. e-Pub 2019.

Book Chapters

1. Feltmate C, Mok SC. Whole genome allelotyping on laser-based microdissected tissue. In: Laser Capture Microdissection: methods and protocols. The Humana Press Inc, 69-77, 2004.
2. Wong KK, Cheng R, Kim JK, Mok SC. Gene expression analysis of ovarian tumors with a cDNA microarray containing ovarian tumor-specific clones. In: Perspectives In Gene Expression. BioTechniques Press, 2003.
3. Mok SC, Schorge JO, Welch WR, Hendrickson MR, Kempson RL. Peritoneal Tumours. In: World Health Organization of Tumours, Pathology & Genetics, Tumours of the Breast and Female Genital Organs. IARC Press, 197-202, 2003.
4. Wong KK, Cheng RS, Berkowitz RS, Mok SC. Gene expression analysis of ovarian cancer cells by cDNA microarray. In: Microarray and Cancer. Eaton Publishing, 127-138, 2002.
5. Mok SC, Lu KH, Ng SW, Yiu GK, Welch WR, Bell DA, Berkowitz RS. Molecular pathogenesis of borderline and invasive ovarian tumors. In: Ovarian Cancer 6. Isis Medical Media, 97-103, 2000.
6. Schorge JO, Mok SC. Molecular pathogenesis of papillary serous carcinoma of the peritoneum. In: Recent Research in Developments in Cancer. Trivandrum: Transworld Research Network, 313-320, 1999.
7. Mok SC, Wong KK, Chan WY, Lau CC, Sager R, Berkowitz RS. Changes in gene expression in ovarian cancer. In: Ovarian Cancer 5. Oxford: Isis Medical Media, 25-33, 1998.
8. Mok SC, Lo KW, Tsao SW. Direct PCR cycle-sequencing of mutated allele detected by PCR-SSCP analysis. In: The PCR Technique: DNA Sequencing II. Eaton Publishing, 69-73, 1997.

Patents

1. Mok SC, Wong KK. Methods of detecting cancer based on osteopontin. Patent Number: 7214501.
2. Ye B, Skates S, Cramer DW, Mok SC. Detection of ovarian cancer based upon alpha-haptoglobin levels. Patent Number: 20030017515.
3. A gene expression profile that predicts ovarian cancer subject response to chemotherapy. Patent Number: 526025.
4. Benjamin TL, Mok D, Cramer DW, Ma Y. Diagnosing and treating cancer cells using Sal2. Patent Number: 20020156039.
5. Mok SC, Ye B, Cramer DW. Osteopontin and fragments as markers for ovarian cancer detection. Patent Number: 6846642.
6. Yin B, Cramer DW, Mok SC. Eosinophil-derived neorotoxin as a marker for ovarian cancer. Patent Number: 20040157251.
7. Ye B, Mok SC, Cramer DW, Berkowitz RS, Skates S. Detection of ovarian cancer based upon alpha-haptoglobin levels. Patent Number: 7112408.
8. Ye B, Mok SC, Cramer DW. Eosinophil-derived neurotoxin as a marker for ovarian cancer detection. Patent Number: 7288383.
9. Mok SC, Wong KK. Methods of detecting cancer based on osteopontin. Patent Number: 7,214,501 B2.
10. Mok SC, Wong KK. Methods of detecting cancer based on prostasin. Patent Number: 6846642.